Vérane Achard1, Frederic Ris2,3, Michel Rouzaud1, Giacomo Puppa4, Nicolas C Buchs2,3, Thomas De Perrot5, Thibaud Koessler6, Cristina Picardi1, Thomas Zilli1,2. 1. Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland. 2. Faculty of Medicine, Geneva University, Geneva, Switzerland. 3. Department of Visceral Surgery, Geneva University Hospital, Geneva, Switzerland. 4. Department of Pathology, Geneva University Hospital, Geneva, Switzerland. 5. Department of Radiology, Geneva University Hospital, Geneva, Switzerland. 6. Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
Abstract
OBJECTIVES: The aim of this pilot study was to investigate in two rectal cancer patients undergoing neoadjuvant chemo-radiotherapy (nCRT) the implant feasibility and dosimetric benefit in sexual organ-sparing of an injectable, absorbable, radiopaque hydrogel spacer. METHODS: Two rectal cancer patients (one male and one female) underwent hydrogel implant between rectum and vagina/prostate before nCRT and curative surgery. A CT scan was performed before and after injection and a comparative dosimetric study was performed testing a standard (45/50 Gy) and a dose escalated (46/55.2 Gy) schedule. RESULTS: In both patients, the spacer implant in the recto-prostatic or recto-vaginal space was feasible and well tolerated. For the male, the dosimetric benefit with spacer was minimal for sexual organs. For the female however, doses delivered to the vagina were significantly reduced with spacer with a mean reduction of more than 5 Gy for both regimens. CONCLUSIONS: For organ preservation protocols and selected sexually active female patients, use of hydrogel spacers can be considered to spare sexual organs from the high radiotherapy dose levels. ADVANCES IN KNOWLEDGE: For females with advanced rectal tumor, a spacer implant between the rectum and the vagina before nCRT is feasible and reduces doses delivered to the vagina.
OBJECTIVES: The aim of this pilot study was to investigate in two rectal cancer patients undergoing neoadjuvant chemo-radiotherapy (nCRT) the implant feasibility and dosimetric benefit in sexual organ-sparing of an injectable, absorbable, radiopaque hydrogel spacer. METHODS: Two rectal cancer patients (one male and one female) underwent hydrogel implant between rectum and vagina/prostate before nCRT and curative surgery. A CT scan was performed before and after injection and a comparative dosimetric study was performed testing a standard (45/50 Gy) and a dose escalated (46/55.2 Gy) schedule. RESULTS: In both patients, the spacer implant in the recto-prostatic or recto-vaginal space was feasible and well tolerated. For the male, the dosimetric benefit with spacer was minimal for sexual organs. For the female however, doses delivered to the vagina were significantly reduced with spacer with a mean reduction of more than 5 Gy for both regimens. CONCLUSIONS: For organ preservation protocols and selected sexually active female patients, use of hydrogel spacers can be considered to spare sexual organs from the high radiotherapy dose levels. ADVANCES IN KNOWLEDGE: For females with advanced rectal tumor, a spacer implant between the rectum and the vagina before nCRT is feasible and reduces doses delivered to the vagina.
Authors: Lawrence B Marks; Ellen D Yorke; Andrew Jackson; Randall K Ten Haken; Louis S Constine; Avraham Eisbruch; Søren M Bentzen; Jiho Nam; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Christina H Son; Ethel Law; Jung Hun Oh; Aditya P Apte; T Jonathan Yang; Elyn Riedel; Abraham J Wu; Joseph O Deasy; Karyn A Goodman Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-28 Impact factor: 7.038
Authors: Benedikt Engels; Koen Tournel; Hendrik Everaert; Anne Hoorens; Alexandra Sermeus; Nicolas Christian; Guy Storme; Dirk Verellen; Mark De Ridder Journal: Int J Radiat Oncol Biol Phys Date: 2011-10-17 Impact factor: 7.038
Authors: Daniel A Hamstra; Neil Mariados; John Sylvester; Dhiren Shah; Eric Gross; Richard Hudes; David Beyer; Steven Kurtzman; Jeffrey Bogart; R Alex Hsi; Michael Kos; Rodney Ellis; Mark Logsdon; Shawn Zimberg; Kevin Forsythe; Hong Zhang; Edward Soffen; Patrick Francke; Constantine Mantz; Peter Rossi; Theodore DeWeese; Stephanie Daignault-Newton; Benjamin W Fischer-Valuck; Anupama Chundury; Hiram A Gay; Walter Bosch; Jeff Michalski Journal: Pract Radiat Oncol Date: 2017-07-19
Authors: Neil Mariados; John Sylvester; Dhiren Shah; Lawrence Karsh; Richard Hudes; David Beyer; Steven Kurtzman; Jeffrey Bogart; R Alex Hsi; Michael Kos; Rodney Ellis; Mark Logsdon; Shawn Zimberg; Kevin Forsythe; Hong Zhang; Edward Soffen; Patrick Francke; Constantine Mantz; Peter Rossi; Theodore DeWeese; Daniel A Hamstra; Walter Bosch; Hiram Gay; Jeff Michalski Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-23 Impact factor: 7.038
Authors: Hiram A Gay; H Joseph Barthold; Elizabeth O'Meara; Walter R Bosch; Issam El Naqa; Rawan Al-Lozi; Seth A Rosenthal; Colleen Lawton; W Robert Lee; Howard Sandler; Anthony Zietman; Robert Myerson; Laura A Dawson; Christopher Willett; Lisa A Kachnic; Anuja Jhingran; Lorraine Portelance; Janice Ryu; William Small; David Gaffney; Akila N Viswanathan; Jeff M Michalski Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-06 Impact factor: 7.038
Authors: Robert J Myerson; Michael C Garofalo; Issam El Naqa; Ross A Abrams; Aditya Apte; Walter R Bosch; Prajnan Das; Leonard L Gunderson; Theodore S Hong; J J John Kim; Christopher G Willett; Lisa A Kachnic Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-29 Impact factor: 7.038